# Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults

> **NCT01767402** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 150 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** PhtD vaccine with/without adjuvant
- **BIOLOGICAL:** Pneumovax 23TM
- **BIOLOGICAL:** NaCl

## Key facts

- **NCT ID:** NCT01767402
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2013-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01767402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01767402, "Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01767402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*